system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
processes shall be in compliance with REACH and RoHS in that they do not add any substances to the resultant Product to the extent currently prohibited by REACH and RoHS. Based upon the information supplied by Third Parties along with Qualigen's knowledge of its own manufacturing processes, Qualigen will certify that, to the best of its knowledge, each of the Products identified in any certification is in compliance with the substance restrictions of REACH and RoHS or is exempt from REACH and RoHS, unless Qualigen has advised Sekisui in advance that any Product or any material incorporated into, or used to produce, any Product ("Material") do not comply with REACH or RoHS. Qualigen has processes in place to ensure proper control of Materials declarations, and segregation of ROHS- compliant and non-compliant Material within Qualigen's manufacturing processes. Qualigen shall maintain REACH and RoHS records and compliance documentation for the amount of time required under REACH or RoHS. Qualigen and Sekisui agree to promptly notify each other if either learns of any developments relating to REACH or RoHS that might impact Sekisui's ability to use any Product or place it on the market in the European Union. Qualigen agrees to notify Sekisui promptly: (1) if there are changes to the REACH registration relevant to the Product; (2) if any of the substances, preparations, or substances in articles purchased by Sekisui meet the criteria referred to in Art. 57 of REACH or are on the candidate list for eventual inclusion in Annex XIV of REACH; (3) if a REACH registration has been rejected by the European Chemicals Agency (ECHA); or (4) of any other development relating to any Product's status under REACH or RoHS where such development might affect Sekisui's ability to use any Product or to place it on the market in the European Union. 6. Management Committee 6.1. Management Committee. Each Party shall, within five (5) business days after the Effective Date, designate four (4) representatives, at least one of whom shall have sufficient authority to enable him or her to make decisions on behalf of the Party he or she represents, to comprise the management committee (the "Management Committee") overseeing the implementation and revision of the Business Plan and Development Plan. Each Party shall (A) promptly notify the other Party in writing of any change in its appointed representatives; and (B) be solely responsible for all travel-related costs and expenses for its respective representatives to attend meetings or to otherwise participate in, or carry out its obligations under, the Management Committee. The Qualigen representatives on the Management Committee shall initially be Paul Rosinack, Michael Poirier, Chris Lotz and Shishir Sinha. The Sekisui representatives on the Management Committee shall initially be Bob Schruender, Lee Lipski, Alan Bauer and Tom Cummins. 10 Source: RITTER PHARMACEUTICALS INC, S-4/A, 3/13/2020 6.2. Meetings. The Management Committee shall be responsible for: (A) meeting quarterly unless otherwise specified in writing by the Parties (in person or via phone/webmeeting) to monitor, review, and discuss the progress under the Business Plan and Development Plan; (B) resolving disputes or disagreements between the Parties with respect to the implementation of the Business Plan and Development Plan; (C) coordinating the exchange of information between the Parties in connection with the activities contemplated by the Business Plan, the Development Plan and this Agreement; (D) confirming the achievement of any milestones resulting in an additional payment under the Development Plan, and (E) carrying out any other responsibilities as are set forth in this Agreement, or that are assigned to it by the Parties. Each Party may invite other representatives of such Party to join any management committee meeting if it would be useful to have their input for a particular agenda topic. For the avoidance of doubt, the Management Committee shall not have the power to amend this Agreement or to waive a Party's compliance with the terms and conditions contained in this Agreement. 6.3. R&D Subcommittee. The Management Committee shall also organize research and development review meetings, which may include members of the Management Committee as well as other representatives of either Party, meeting monthly unless otherwise specified in writing by the Parties (in person or via phone/webmeeting) to monitor, review, and discuss the progress of the development of future Products and manufacturing capability in accordance with the Development Plan, including a review of all applicable data and an assessment of resources. 6.4. Quality Subcommittee. The Management Committee may also organize quality review meetings, which may include members of the Management Committee as
"""

Extract the exact clause related to "Volume Restriction" from the excerpt above.